Results 201 to 210 of about 169,930 (262)

MAIT Cells Suppress IgE‐Mediated Asthma via IFNγ‐Dependent B Cell Regulation

Allergy, EarlyView.
In this study, we demonstrate that MAIT cell antagonism during sensitization and challenge with HDM worsens the development of airway hyperreactivity without effects on type 2 or 17 associated cytokine production or lung inflammation. Rather, MAIT cells appear to regulate HDM‐induced asthma through direct inhibition of IgE production.
Angela M. Cannata, Jaclyn W. McAlees, Julie M. Hargis, Archana Shankar, Shouxiong Huang, Senad Divanovic, Ian P. Lewkowich   +6 more
wiley   +1 more source

Serum anti-β2 spectrin IgA antibodies are produced in a CD4 T cell-independent manner in IgA nephropathy model mouse. [PDF]

Front Immunol
Iwasaki H, Nihei Y, Suzuki H, Kitamura D, Suzuki Y.   +4 more
europepmc   +1 more source

Infection control in the brain and the eye

Acta Ophthalmologica, EarlyView.
Abstract The Central Nervous System (CNS), comprising the brain and the eye, is considered to have a ‘privileged’ mechanism for dealing with immunological challenge (immune privilege, IP). CNS IP has been revealed through experiments using foreign protein antigens and cell and tissue alloantigens (grafts), but evidence for a role for IP in modulating ...
John V. Forrester, Paul G. McMenamin, Samantha J. Dando   +2 more
wiley   +1 more source

Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine. [PDF]

Sci Adv
Eshaghi B, Wang EY, Mursalova S, Forster TA, Lasrado N, Tian J, Artzi D, Lin SQ, Wu Z, Yang X, Chung W, Sadeghi I, Garcia J, Chen Z, Sheridan O, Das R, Lau A, Gurram A, Mainou BA, Jones KAV, Liu Y, Barouch DH, von Andrian U, Langer R, Jaklenec A.   +24 more
europepmc   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Human Blood IgA⁺ Memory B Cells Differ From IgG⁺ B Cells by Expressing Gut-Homing and Regulatory Markers. [PDF]

Eur J Immunol
Le Gal L, Boussamet L, Garcia A, Morille J, Dugast E, Nicot AB, Laplaud DA, Berthelot L.   +7 more
europepmc   +1 more source

Malassezia‐Induced Type 2 Immunity in Head Neck Shoulder Type Atopic Dermatitis

Allergy, EarlyView.
I. Suhrkamp, T. Heidland, C. Saft, A. K. Kamps, S. Edenhart, O. Kniemeyer, W. Francuzik, S. Weidinger, P. Bacher, C. Bang, G. Heine   +10 more
wiley   +1 more source

Immune System Development—Pro Tips for Paediatricians

Acta Paediatrica, EarlyView.
ABSTRACT There are many misconceptions about the immune system in children, its impact on infectious disease susceptibility and its role in the rapidly increasing rates of immune mediated diseases in industrialized societies. In this mini review, I will discuss common believes and the data supporting or countering such believes, with a focus on ...
Petter Brodin
wiley   +1 more source

Rapidly Progressive IgA Nephropathy in a Patient With a History of Breast Cancer: A Case Report and Literature Review. [PDF]

Case Rep Nephrol
Montesinos RL, Marca EQ, Torrico CA, Herbas DS, Limachi LC, Arenas ZT, Mamani WV.   +6 more
europepmc   +1 more source

Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

British Journal of Haematology, EarlyView.
ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.
Carlos Jimenez‐Mira, Natalia Tovar, Núria Martínez‐Cibrián, Verónica González‐Calle, Nil Albiol, Nieves López‐Muñoz, Aina Oliver‐Caldés, Azucena González, José Miguel Mateos, Marta Español‐Rego, Laura Rosiñol, Manel Juan, Paola Charry, José María Sanchez‐Pina, Sergio Navarro, Daniel Munárriz, Lucía López‐Corral, Valentín Ortiz‐Maldonado, Sara Varea, Eulalia Olesti, Julio Delgado, Álvaro Urbano‐Ispizua, Joaquín Martínez‐López, María Victoria Mateos, Luis Gerardo Rodríguez‐Lobato, Carlos Fernández de Larrea   +25 more
wiley   +1 more source